Can Halozyme Therapeutics Continue Its Momentum in 2020?

Halozyme Therapeutics (NASDAQ: HALO) underperformed the broader market in 2019 by 8%. The company cruised into 2020 with its stock up more than 10% year to date, but investors may be wondering if this stock can outperform the S&P 500 this year.